Evidence map›Paper›PMID 41669647›Full record

ArticleJournal of medical cases2026

Perforated Small Intestinal Diffuse Large B-Cell Lymphoma Successfully Managed With Surgical Resection and Staged Introduction of Polatuzumab Vedotin-Based Chemotherapy.

Shunsuke Yamada, Yoshikazu Ikoma, Tomohiro Aizaki, Kiichi Otani, Yuto Kaneda, Yuta Sato, Takuro Matsumoto, Nobuhiko Nakamura, Hiroshi Nakamura, Nobuhisa Matsuhashi and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shunsuke YamadaDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Yoshikazu IkomaDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Tomohiro AizakiDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Kiichi OtaniDepartment of Gastroenterology, Gifu University Hospital, Gifu, Japan.
Yuto KanedaDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Yuta SatoDepartment of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Takuro MatsumotoDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Nobuhiko NakamuraDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Hiroshi NakamuraDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Nobuhisa MatsuhashiDepartment of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Nobuhiro KanemuraDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Masahito ShimizuDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) is a vincristine-free regimen recently approved for untreated diffuse large B-cell lymphoma (DLBCL). However, its safety in the early postoperative setting remains unclear. We report a case of primary intestinal DLBCL with suspected perforation managed with surgical resection followed by staged introduction of Pola-R-CHP. Rituximab was started on postoperative day 11, followed by CHP on day 15 as the first cycle of R-CHP. Pola was added from cycle 2. The patient showed an initial tumor reduction without serious gastrointestinal (GI) toxicity. This case suggests that staged introduction of Pola-R-CHP may minimize postoperative GI risk while maintaining safety.

Indexed as

Diffuse large B-cell lymphomaGastrointestinal lymphomaIntestinal perforationPolatuzumab vedotinSurgical procedures

Identifiers

PMID41669647
PMCPMC12885135

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.